カテゴリ： LP Information, 世界, 医療/バイオ

高尿酸血症治療薬の世界市場2022-2028：NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他

■ 英語タイトル：Global Hyperuricemia Drugs Market Growth 2022-2028

調査会社LP Information社が発行したリサーチレポート（データ管理コード：LP22DC5005）■ 発行会社/調査会社：LP Information
■ 商品コード：LP22DC5005
■ 発行日：2022年12月
■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
■ 産業分野：医薬品
■ ページ数：104
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[高尿酸血症治療薬の世界市場2022-2028：NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

高尿酸血症治療薬のグローバル市場規模は、2021年のxxx百万ドルから2028年までにxxx百万ドルに増加すると推定されており、2022年～2028年の年平均成長率（CAGR）はxx%を示しています。COVID-19とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対するパンデミックの直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
高尿酸血症治療薬のアジア太平洋市場は、2022年にxxx百万ドルの市場規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。高尿酸血症治療薬の米国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。高尿酸血症治療薬のヨーロッパ市場は、2022年にxxx百万ドルの規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。高尿酸血症治療薬の中国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要な高尿酸血症治療薬関連企業としては、Pfizer Inc、 F. Hoffmann-La Roche Ltd、 Mylan NV、 Fresenius Kabi AG、 Hikma Pharmaceuticals PLC、 Novartis AG、 Teva Pharmaceutical Industries Ltd.、 Bayer AG、 Bristol Myers Squibb、 GSK Plc、 Sun Pharmaceutical Industries Ltd、 Dr. Reddy's Laboratories Ltd、 Endo International plcなどをカバーしています。売上の面では世界最大の2社が2021年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながら高尿酸血症治療薬のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリュー チェーン分析などのミクロの詳細にまで及びます。当レポートは読者がパンデミックおよびロシア・ウクライナ戦争中に世界中で高尿酸血症治療薬市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、高尿酸血症治療薬のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2021年で、市場の予測は2022年～2028年までのものです。

*** 市場セグメンテーション ***

この調査では高尿酸血症治療薬市場を細分化し、種類別 (NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他)、用途別 (痛風、腎結石、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他

・用途別区分：痛風、腎結石、その他

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：高尿酸血症治療薬の範囲、調査方法など
第2章：エグゼクティブサマリー、世界の高尿酸血症治療薬市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2017年～2022年までの推移データ、および2028年までの市場予測
第3章：企業別高尿酸血症治療薬の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別の高尿酸血症治療薬の販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界の高尿酸血症治療薬市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：高尿酸血症治療薬の年間販売量2017-2028、地域別現状・将来分析
・高尿酸血症治療薬の種類別セグメント：NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他
・高尿酸血症治療薬の種類別販売量：2017-2022年の販売量、売上、市場シェア、販売価格
・高尿酸血症治療薬の用途別セグメント：痛風、腎結石、その他
・高尿酸血症治療薬の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界の高尿酸血症治療薬市場
・企業別のグローバル高尿酸血症治療薬市場データ：2020-2022年の年間販売量、市場シェア
・企業別の高尿酸血症治療薬の年間売上：2020-2022年の売上、市場シェア
・企業別の高尿酸血症治療薬販売価格
・主要企業の高尿酸血症治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

高尿酸血症治療薬の地域別レビュー
・地域別の高尿酸血症治療薬市場規模2017-2022：年間販売量、売上
・主要国別の高尿酸血症治療薬市場規模2017-2022：年間販売量、売上
・アメリカ州の高尿酸血症治療薬販売の成長
・アジア太平洋の高尿酸血症治療薬販売の成長
・ヨーロッパの高尿酸血症治療薬販売の成長
・中東・アフリカの高尿酸血症治療薬販売の成長

アメリカ州市場
・アメリカ州の国別の高尿酸血症治療薬販売量、売上（2017-2022）
・アメリカ州の高尿酸血症治療薬の種類別販売量
・アメリカ州の高尿酸血症治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別の高尿酸血症治療薬販売量、売上（2017-2022）
・アジア太平洋の高尿酸血症治療薬の種類別販売量
・アジア太平洋の高尿酸血症治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の高尿酸血症治療薬販売量、売上（2017-2022）
・ヨーロッパの高尿酸血症治療薬の種類別販売量
・ヨーロッパの高尿酸血症治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の高尿酸血症治療薬販売量、売上（2017-2022）
・中東・アフリカの高尿酸血症治療薬の種類別販売量
・中東・アフリカの高尿酸血症治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・高尿酸血症治療薬の製造コスト構造分析
・高尿酸血症治療薬の製造プロセス分析
・高尿酸血症治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・高尿酸血症治療薬の主要なグローバル販売業者
・高尿酸血症治療薬の主要なグローバル顧客

地域別の高尿酸血症治療薬市場予測レビュー
・地域別の高尿酸血症治療薬市場規模予測（2023-2028）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・高尿酸血症治療薬の種類別市場規模予測
・高尿酸血症治療薬の用途別市場規模予測

主要企業分析
Pfizer Inc、 F. Hoffmann-La Roche Ltd、 Mylan NV、 Fresenius Kabi AG、 Hikma Pharmaceuticals PLC、 Novartis AG、 Teva Pharmaceutical Industries Ltd.、 Bayer AG、 Bristol Myers Squibb、 GSK Plc、 Sun Pharmaceutical Industries Ltd、 Dr. Reddy's Laboratories Ltd、 Endo International plc
・企業情報
・高尿酸血症治療薬製品
・高尿酸血症治療薬販売量、売上、価格、粗利益（2020-2022）
・主要ビジネス概要
・最新動向

調査の結果

Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout.
The global market for Hyperuricemia Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Hyperuricemia Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Hyperuricemia Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Hyperuricemia Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Hyperuricemia Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Hyperuricemia Drugs players cover Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan NV, Fresenius Kabi AG and Hikma Pharmaceuticals PLC, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

[Report Coverage]
This latest report provides a deep insight into the global Hyperuricemia Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Hyperuricemia Drugs market, with both quantitative and qualitative data, to help readers understand how the Hyperuricemia Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Hyperuricemia Drugs market and forecasts the market size by Type (NSAIDs, Xanthine Oxidase Inhibitor and Selective Uric Acid Reabsorption Inhibitor), by Application (Gout, Renal Calculus and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
NSAIDs
Xanthine Oxidase Inhibitor
Selective Uric Acid Reabsorption Inhibitor
Carbonic Anhydrase Inhibitor
Glucocorticoid
Other
Segmentation by application
Gout
Renal Calculus
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Pfizer Inc
F. Hoffmann-La Roche Ltd
Mylan NV
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd.
Bayer AG
Bristol Myers Squibb
GSK Plc
Sun Pharmaceutical Industries Ltd
Dr. Reddy’s Laboratories Ltd
Endo International plc

[Chapter Introduction]
Chapter 1: Scope of Hyperuricemia Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global Hyperuricemia Drugs market size (sales and revenue) and CAGR, Hyperuricemia Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Hyperuricemia Drugs sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Hyperuricemia Drugs sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Hyperuricemia Drugs market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG and Bristol Myers Squibb, etc.
Chapter 14: Research Findings and Conclusion

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hyperuricemia Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Hyperuricemia Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Hyperuricemia Drugs by Country/Region, 2017, 2022 & 2028
2.2 Hyperuricemia Drugs Segment by Type
2.2.1 NSAIDs
2.2.2 Xanthine Oxidase Inhibitor
2.2.3 Selective Uric Acid Reabsorption Inhibitor
2.2.4 Carbonic Anhydrase Inhibitor
2.2.5 Glucocorticoid
2.2.6 Other
2.3 Hyperuricemia Drugs Sales by Type
2.3.1 Global Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Hyperuricemia Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Hyperuricemia Drugs Sale Price by Type (2017-2022)
2.4 Hyperuricemia Drugs Segment by Application
2.4.1 Gout
2.4.2 Renal Calculus
2.4.3 Other
2.5 Hyperuricemia Drugs Sales by Application
2.5.1 Global Hyperuricemia Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Hyperuricemia Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Hyperuricemia Drugs Sale Price by Application (2017-2022)
3 Global Hyperuricemia Drugs by Company
3.1 Global Hyperuricemia Drugs Breakdown Data by Company
3.1.1 Global Hyperuricemia Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Hyperuricemia Drugs Sales Market Share by Company (2020-2022)
3.2 Global Hyperuricemia Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Hyperuricemia Drugs Revenue by Company (2020-2022)
3.2.2 Global Hyperuricemia Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Hyperuricemia Drugs Sale Price by Company
3.4 Key Manufacturers Hyperuricemia Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hyperuricemia Drugs Product Location Distribution
3.4.2 Players Hyperuricemia Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hyperuricemia Drugs by Geographic Region
4.1 World Historic Hyperuricemia Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Hyperuricemia Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Hyperuricemia Drugs Annual Revenue by Geographic Region
4.2 World Historic Hyperuricemia Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Hyperuricemia Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Hyperuricemia Drugs Annual Revenue by Country/Region
4.3 Americas Hyperuricemia Drugs Sales Growth
4.4 APAC Hyperuricemia Drugs Sales Growth
4.5 Europe Hyperuricemia Drugs Sales Growth
4.6 Middle East & Africa Hyperuricemia Drugs Sales Growth
5 Americas
5.1 Americas Hyperuricemia Drugs Sales by Country
5.1.1 Americas Hyperuricemia Drugs Sales by Country (2017-2022)
5.1.2 Americas Hyperuricemia Drugs Revenue by Country (2017-2022)
5.2 Americas Hyperuricemia Drugs Sales by Type
5.3 Americas Hyperuricemia Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hyperuricemia Drugs Sales by Region
6.1.1 APAC Hyperuricemia Drugs Sales by Region (2017-2022)
6.1.2 APAC Hyperuricemia Drugs Revenue by Region (2017-2022)
6.2 APAC Hyperuricemia Drugs Sales by Type
6.3 APAC Hyperuricemia Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hyperuricemia Drugs by Country
7.1.1 Europe Hyperuricemia Drugs Sales by Country (2017-2022)
7.1.2 Europe Hyperuricemia Drugs Revenue by Country (2017-2022)
7.2 Europe Hyperuricemia Drugs Sales by Type
7.3 Europe Hyperuricemia Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hyperuricemia Drugs by Country
8.1.1 Middle East & Africa Hyperuricemia Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Hyperuricemia Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Hyperuricemia Drugs Sales by Type
8.3 Middle East & Africa Hyperuricemia Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hyperuricemia Drugs
10.3 Manufacturing Process Analysis of Hyperuricemia Drugs
10.4 Industry Chain Structure of Hyperuricemia Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hyperuricemia Drugs Distributors
11.3 Hyperuricemia Drugs Customer
12 World Forecast Review for Hyperuricemia Drugs by Geographic Region
12.1 Global Hyperuricemia Drugs Market Size Forecast by Region
12.1.1 Global Hyperuricemia Drugs Forecast by Region (2023-2028)
12.1.2 Global Hyperuricemia Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hyperuricemia Drugs Forecast by Type
12.7 Global Hyperuricemia Drugs Forecast by Application
13 Key Players Analysis
13.1 Pfizer Inc
13.1.1 Pfizer Inc Company Information
13.1.2 Pfizer Inc Hyperuricemia Drugs Product Offered
13.1.3 Pfizer Inc Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Inc Main Business Overview
13.1.5 Pfizer Inc Latest Developments
13.2 F. Hoffmann-La Roche Ltd
13.2.1 F. Hoffmann-La Roche Ltd Company Information
13.2.2 F. Hoffmann-La Roche Ltd Hyperuricemia Drugs Product Offered
13.2.3 F. Hoffmann-La Roche Ltd Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.2.5 F. Hoffmann-La Roche Ltd Latest Developments
13.3 Mylan NV
13.3.1 Mylan NV Company Information
13.3.2 Mylan NV Hyperuricemia Drugs Product Offered
13.3.3 Mylan NV Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Mylan NV Main Business Overview
13.3.5 Mylan NV Latest Developments
13.4 Fresenius Kabi AG
13.4.1 Fresenius Kabi AG Company Information
13.4.2 Fresenius Kabi AG Hyperuricemia Drugs Product Offered
13.4.3 Fresenius Kabi AG Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Fresenius Kabi AG Main Business Overview
13.4.5 Fresenius Kabi AG Latest Developments
13.5 Hikma Pharmaceuticals PLC
13.5.1 Hikma Pharmaceuticals PLC Company Information
13.5.2 Hikma Pharmaceuticals PLC Hyperuricemia Drugs Product Offered
13.5.3 Hikma Pharmaceuticals PLC Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Hikma Pharmaceuticals PLC Main Business Overview
13.5.5 Hikma Pharmaceuticals PLC Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Hyperuricemia Drugs Product Offered
13.6.3 Novartis AG Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Teva Pharmaceutical Industries Ltd.
13.7.1 Teva Pharmaceutical Industries Ltd. Company Information
13.7.2 Teva Pharmaceutical Industries Ltd. Hyperuricemia Drugs Product Offered
13.7.3 Teva Pharmaceutical Industries Ltd. Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
13.7.5 Teva Pharmaceutical Industries Ltd. Latest Developments
13.8 Bayer AG
13.8.1 Bayer AG Company Information
13.8.2 Bayer AG Hyperuricemia Drugs Product Offered
13.8.3 Bayer AG Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Bayer AG Main Business Overview
13.8.5 Bayer AG Latest Developments
13.9 Bristol Myers Squibb
13.9.1 Bristol Myers Squibb Company Information
13.9.2 Bristol Myers Squibb Hyperuricemia Drugs Product Offered
13.9.3 Bristol Myers Squibb Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Bristol Myers Squibb Main Business Overview
13.9.5 Bristol Myers Squibb Latest Developments
13.10 GSK Plc
13.10.1 GSK Plc Company Information
13.10.2 GSK Plc Hyperuricemia Drugs Product Offered
13.10.3 GSK Plc Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 GSK Plc Main Business Overview
13.10.5 GSK Plc Latest Developments
13.11 Sun Pharmaceutical Industries Ltd
13.11.1 Sun Pharmaceutical Industries Ltd Company Information
13.11.2 Sun Pharmaceutical Industries Ltd Hyperuricemia Drugs Product Offered
13.11.3 Sun Pharmaceutical Industries Ltd Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.11.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.12 Dr. Reddy’s Laboratories Ltd
13.12.1 Dr. Reddy’s Laboratories Ltd Company Information
13.12.2 Dr. Reddy’s Laboratories Ltd Hyperuricemia Drugs Product Offered
13.12.3 Dr. Reddy’s Laboratories Ltd Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Dr. Reddy’s Laboratories Ltd Main Business Overview
13.12.5 Dr. Reddy’s Laboratories Ltd Latest Developments
13.13 Endo International plc
13.13.1 Endo International plc Company Information
13.13.2 Endo International plc Hyperuricemia Drugs Product Offered
13.13.3 Endo International plc Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Endo International plc Main Business Overview
13.13.5 Endo International plc Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Hyperuricemia Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Hyperuricemia Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of NSAIDs
Table 4. Major Players of Xanthine Oxidase Inhibitor
Table 5. Major Players of Selective Uric Acid Reabsorption Inhibitor
Table 6. Major Players of Carbonic Anhydrase Inhibitor
Table 7. Major Players of Glucocorticoid
Table 8. Major Players of Other
Table 9. Global Hyperuricemia Drugs Sales by Type (2017-2022) & (K Units)
Table 10. Global Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
Table 11. Global Hyperuricemia Drugs Revenue by Type (2017-2022) & ($ million)
Table 12. Global Hyperuricemia Drugs Revenue Market Share by Type (2017-2022)
Table 13. Global Hyperuricemia Drugs Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Hyperuricemia Drugs Sales by Application (2017-2022) & (K Units)
Table 15. Global Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Table 16. Global Hyperuricemia Drugs Revenue by Application (2017-2022)
Table 17. Global Hyperuricemia Drugs Revenue Market Share by Application (2017-2022)
Table 18. Global Hyperuricemia Drugs Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Hyperuricemia Drugs Sales by Company (2020-2022) & (K Units)
Table 20. Global Hyperuricemia Drugs Sales Market Share by Company (2020-2022)
Table 21. Global Hyperuricemia Drugs Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Hyperuricemia Drugs Revenue Market Share by Company (2020-2022)
Table 23. Global Hyperuricemia Drugs Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Hyperuricemia Drugs Producing Area Distribution and Sales Area
Table 25. Players Hyperuricemia Drugs Products Offered
Table 26. Hyperuricemia Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Hyperuricemia Drugs Sales by Geographic Region (2017-2022) & (K Units)
Table 30. Global Hyperuricemia Drugs Sales Market Share Geographic Region (2017-2022)
Table 31. Global Hyperuricemia Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Hyperuricemia Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Hyperuricemia Drugs Sales by Country/Region (2017-2022) & (K Units)
Table 34. Global Hyperuricemia Drugs Sales Market Share by Country/Region (2017-2022)
Table 35. Global Hyperuricemia Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Hyperuricemia Drugs Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Hyperuricemia Drugs Sales by Country (2017-2022) & (K Units)
Table 38. Americas Hyperuricemia Drugs Sales Market Share by Country (2017-2022)
Table 39. Americas Hyperuricemia Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Hyperuricemia Drugs Revenue Market Share by Country (2017-2022)
Table 41. Americas Hyperuricemia Drugs Sales by Type (2017-2022) & (K Units)
Table 42. Americas Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
Table 43. Americas Hyperuricemia Drugs Sales by Application (2017-2022) & (K Units)
Table 44. Americas Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Table 45. APAC Hyperuricemia Drugs Sales by Region (2017-2022) & (K Units)
Table 46. APAC Hyperuricemia Drugs Sales Market Share by Region (2017-2022)
Table 47. APAC Hyperuricemia Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Hyperuricemia Drugs Revenue Market Share by Region (2017-2022)
Table 49. APAC Hyperuricemia Drugs Sales by Type (2017-2022) & (K Units)
Table 50. APAC Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
Table 51. APAC Hyperuricemia Drugs Sales by Application (2017-2022) & (K Units)
Table 52. APAC Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Table 53. Europe Hyperuricemia Drugs Sales by Country (2017-2022) & (K Units)
Table 54. Europe Hyperuricemia Drugs Sales Market Share by Country (2017-2022)
Table 55. Europe Hyperuricemia Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Hyperuricemia Drugs Revenue Market Share by Country (2017-2022)
Table 57. Europe Hyperuricemia Drugs Sales by Type (2017-2022) & (K Units)
Table 58. Europe Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
Table 59. Europe Hyperuricemia Drugs Sales by Application (2017-2022) & (K Units)
Table 60. Europe Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Hyperuricemia Drugs Sales by Country (2017-2022) & (K Units)
Table 62. Middle East & Africa Hyperuricemia Drugs Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Hyperuricemia Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Hyperuricemia Drugs Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Hyperuricemia Drugs Sales by Type (2017-2022) & (K Units)
Table 66. Middle East & Africa Hyperuricemia Drugs Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Hyperuricemia Drugs Sales by Application (2017-2022) & (K Units)
Table 68. Middle East & Africa Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Hyperuricemia Drugs
Table 70. Key Market Challenges & Risks of Hyperuricemia Drugs
Table 71. Key Industry Trends of Hyperuricemia Drugs
Table 72. Hyperuricemia Drugs Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Hyperuricemia Drugs Distributors List
Table 75. Hyperuricemia Drugs Customer List
Table 76. Global Hyperuricemia Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 77. Global Hyperuricemia Drugs Sales Market Forecast by Region
Table 78. Global Hyperuricemia Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Hyperuricemia Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Hyperuricemia Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Americas Hyperuricemia Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Hyperuricemia Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 83. APAC Hyperuricemia Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Hyperuricemia Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Europe Hyperuricemia Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Hyperuricemia Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 87. Middle East & Africa Hyperuricemia Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Hyperuricemia Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 89. Global Hyperuricemia Drugs Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Hyperuricemia Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Hyperuricemia Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Hyperuricemia Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 93. Global Hyperuricemia Drugs Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Hyperuricemia Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Hyperuricemia Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 96. Pfizer Inc Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Pfizer Inc Hyperuricemia Drugs Product Offered
Table 98. Pfizer Inc Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. Pfizer Inc Main Business
Table 100. Pfizer Inc Latest Developments
Table 101. F. Hoffmann-La Roche Ltd Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. F. Hoffmann-La Roche Ltd Hyperuricemia Drugs Product Offered
Table 103. F. Hoffmann-La Roche Ltd Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. F. Hoffmann-La Roche Ltd Main Business
Table 105. F. Hoffmann-La Roche Ltd Latest Developments
Table 106. Mylan NV Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Mylan NV Hyperuricemia Drugs Product Offered
Table 108. Mylan NV Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. Mylan NV Main Business
Table 110. Mylan NV Latest Developments
Table 111. Fresenius Kabi AG Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Fresenius Kabi AG Hyperuricemia Drugs Product Offered
Table 113. Fresenius Kabi AG Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Fresenius Kabi AG Main Business
Table 115. Fresenius Kabi AG Latest Developments
Table 116. Hikma Pharmaceuticals PLC Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Hikma Pharmaceuticals PLC Hyperuricemia Drugs Product Offered
Table 118. Hikma Pharmaceuticals PLC Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Hikma Pharmaceuticals PLC Main Business
Table 120. Hikma Pharmaceuticals PLC Latest Developments
Table 121. Novartis AG Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Novartis AG Hyperuricemia Drugs Product Offered
Table 123. Novartis AG Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Novartis AG Main Business
Table 125. Novartis AG Latest Developments
Table 126. Teva Pharmaceutical Industries Ltd. Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Teva Pharmaceutical Industries Ltd. Hyperuricemia Drugs Product Offered
Table 128. Teva Pharmaceutical Industries Ltd. Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Teva Pharmaceutical Industries Ltd. Main Business
Table 130. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 131. Bayer AG Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Bayer AG Hyperuricemia Drugs Product Offered
Table 133. Bayer AG Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Bayer AG Main Business
Table 135. Bayer AG Latest Developments
Table 136. Bristol Myers Squibb Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Bristol Myers Squibb Hyperuricemia Drugs Product Offered
Table 138. Bristol Myers Squibb Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Bristol Myers Squibb Main Business
Table 140. Bristol Myers Squibb Latest Developments
Table 141. GSK Plc Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. GSK Plc Hyperuricemia Drugs Product Offered
Table 143. GSK Plc Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. GSK Plc Main Business
Table 145. GSK Plc Latest Developments
Table 146. Sun Pharmaceutical Industries Ltd Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 147. Sun Pharmaceutical Industries Ltd Hyperuricemia Drugs Product Offered
Table 148. Sun Pharmaceutical Industries Ltd Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 149. Sun Pharmaceutical Industries Ltd Main Business
Table 150. Sun Pharmaceutical Industries Ltd Latest Developments
Table 151. Dr. Reddy's Laboratories Ltd Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 152. Dr. Reddy's Laboratories Ltd Hyperuricemia Drugs Product Offered
Table 153. Dr. Reddy's Laboratories Ltd Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 154. Dr. Reddy's Laboratories Ltd Main Business
Table 155. Dr. Reddy's Laboratories Ltd Latest Developments
Table 156. Endo International plc Basic Information, Hyperuricemia Drugs Manufacturing Base, Sales Area and Its Competitors
Table 157. Endo International plc Hyperuricemia Drugs Product Offered
Table 158. Endo International plc Hyperuricemia Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 159. Endo International plc Main Business
Table 160. Endo International plc Latest Developments
List of Figures
Figure 1. Picture of Hyperuricemia Drugs
Figure 2. Hyperuricemia Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hyperuricemia Drugs Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Hyperuricemia Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Hyperuricemia Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of NSAIDs
Figure 10. Product Picture of Xanthine Oxidase Inhibitor
Figure 11. Product Picture of Selective Uric Acid Reabsorption Inhibitor
Figure 12. Product Picture of Carbonic Anhydrase Inhibitor
Figure 13. Product Picture of Glucocorticoid
Figure 14. Product Picture of Other
Figure 15. Global Hyperuricemia Drugs Sales Market Share by Type in 2021
Figure 16. Global Hyperuricemia Drugs Revenue Market Share by Type (2017-2022)
Figure 17. Hyperuricemia Drugs Consumed in Gout
Figure 18. Global Hyperuricemia Drugs Market: Gout (2017-2022) & (K Units)
Figure 19. Hyperuricemia Drugs Consumed in Renal Calculus
Figure 20. Global Hyperuricemia Drugs Market: Renal Calculus (2017-2022) & (K Units)
Figure 21. Hyperuricemia Drugs Consumed in Other
Figure 22. Global Hyperuricemia Drugs Market: Other (2017-2022) & (K Units)
Figure 23. Global Hyperuricemia Drugs Sales Market Share by Application (2017-2022)
Figure 24. Global Hyperuricemia Drugs Revenue Market Share by Application in 2021
Figure 25. Hyperuricemia Drugs Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Hyperuricemia Drugs Revenue Market Share by Company in 2021
Figure 27. Global Hyperuricemia Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Hyperuricemia Drugs Revenue Market Share by Geographic Region in 2021
Figure 29. Global Hyperuricemia Drugs Sales Market Share by Region (2017-2022)
Figure 30. Global Hyperuricemia Drugs Revenue Market Share by Country/Region in 2021
Figure 31. Americas Hyperuricemia Drugs Sales 2017-2022 (K Units)
Figure 32. Americas Hyperuricemia Drugs Revenue 2017-2022 ($ Millions)
Figure 33. APAC Hyperuricemia Drugs Sales 2017-2022 (K Units)
Figure 34. APAC Hyperuricemia Drugs Revenue 2017-2022 ($ Millions)
Figure 35. Europe Hyperuricemia Drugs Sales 2017-2022 (K Units)
Figure 36. Europe Hyperuricemia Drugs Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Hyperuricemia Drugs Sales 2017-2022 (K Units)
Figure 38. Middle East & Africa Hyperuricemia Drugs Revenue 2017-2022 ($ Millions)
Figure 39. Americas Hyperuricemia Drugs Sales Market Share by Country in 2021
Figure 40. Americas Hyperuricemia Drugs Revenue Market Share by Country in 2021
Figure 41. United States Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Hyperuricemia Drugs Sales Market Share by Region in 2021
Figure 46. APAC Hyperuricemia Drugs Revenue Market Share by Regions in 2021
Figure 47. China Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Hyperuricemia Drugs Sales Market Share by Country in 2021
Figure 54. Europe Hyperuricemia Drugs Revenue Market Share by Country in 2021
Figure 55. Germany Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Hyperuricemia Drugs Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Hyperuricemia Drugs Revenue Market Share by Country in 2021
Figure 62. Egypt Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Hyperuricemia Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Hyperuricemia Drugs in 2021
Figure 68. Manufacturing Process Analysis of Hyperuricemia Drugs
Figure 69. Industry Chain Structure of Hyperuricemia Drugs
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 犬アトピー性皮膚炎のグローバル市場：グルココルチコイド、免疫抑制剤、モノクローナル抗体、その他
  • 乾癬性関節炎治療のグローバル市場：NSAIDs（非ステロイド性抗炎症薬）、DMARDs（疾患修飾性抗リウマチ薬）、生物製剤、その他
  • 世界の全身性エリテマトーデス（SLE）治療薬市場予測2024年-2032年：薬効分類別（抗マラリア薬、非ステロイド性抗炎症薬（NSAIDS）、細胞障害性・免疫抑制薬、生物学的製剤、その他）、投与形態別（静脈内投与、皮下投与、経口投与）、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(LP22DC5005 )"高尿酸血症治療薬の世界市場2022-2028：NSAIDs、キサンチンオキシダーゼ阻害剤、選択的尿酸再吸収阻害剤、炭酸脱水酵素阻害剤、グルココルチコイド、その他" (英文：Global Hyperuricemia Drugs Market Growth 2022-2028)はLP Information社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。